Conclusion
The USP–ChP annual scientific meeting brought together several experts to discuss the expanding use of TCM and associated
regulatory issues. Modern research is ongoing in China and Western research facilities regarding the mechanisms of TCM's pharmacological
action. USP will continue to exercise its role in developing TCM singular botanical ingredients via the dietary supplements and active drug and excipient moieties model.
James C. Griffiths, PhD, is vice-president of food, dietary supplements, and excipient standards at the US Pharmacopeial Convention, 12601 Twinbrook
Parkway, Rockville, MD 20852-1709, jcg@usp.org
References
1. USP (Boston: Wells and Lilly, 1820).
2. FDA, Food Additive Petition Expedited Review—Guidance for Industry and Center for Food Safety and Applied Nutrition Staff (Rockville, MD, 1999),
http://www.cfsan.fda.gov/~dms/opa-expe.html accessed Jan. 26, 2009.
3. FDA, Guidance for Industry: Frequently Asked Questions about GRAS (Rockville, MD, 2004),
http://www.cfsan.fda.gov/~dms/grasguid.html accessed Jan. 26, 2009.
4. FDA, Numerical Listing of GRAS Notices (Rockville, MD, 2008),
http://www.cfsan.fda.gov/~rdb/opa-gras.html accessed Jan. 26, 2009.
5. PL 103-417, Dietary Supplement Health and Education Act, 1994,
http://www.fda.gov/opacom/laws/DSHEA.html accessed Jan. 26, 2009.
6. L. Bhattacharyya et al., "The Value of USP Public Standards for Therapeutic Products," Pharm. Res.,
21, 1725–1731 (2004).
7. R.L. Williams et al., "Official USP Reference Standards: Metrology Concepts, Overview, and Scientific Issues and Opportunities,"
J.
Pharm. Biomed. Anal., 40, 3–15 (2006).
|
